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Introduction
Mechanical forces generated in epithelial cells regulate sev­
eral cellular processes, including apical constriction, cell inter­
calation, planar cell polarity regulation, cell sorting, tension 
sensing, and the formation and maintenance of the adherens junc­
tion (Owaribe et al., 1981; Ivanov et al., 2004, 2007; Shewan 
et al., 2005; Miyake et al., 2006; Lecuit and Lenne, 2007; 
Yamazaki et al., 2008; Zallen and Blankenship, 2008; le Duc 
et  al.,  2010;  Smutny  et  al.,  2010;  Smutny  and  Yap,  2010;   
Yonemura et al., 2010). The forces themselves are mainly gen­
erated by an F­actin–myosin II bundle called the circumfer­
ential actomyosin belt, which is positioned in the apical portion   
of the cells as a ringlike structure along apical cell–cell junc­
tions  (tight  and  adherens  junctions  in  vertebrates;  Owaribe   
et  al.,  1981; Yamazaki  et  al.,  2008;  Smutny  et  al.,  2010;   
Yonemura et al., 2010). Recent studies identified some molecu­
lar pathways regulating this: for example, the Rho–Rock and 
Rap1 pathways were reported to be responsible for proper 
organization of myosin II isoforms along apical cell–cell junc­
tions (Smutny et al., 2010). As another example, shroom3 was 
reported to regulate myosin II activity by recruiting Rock to 
apical cell–cell junctions, thereby inducing apical constriction 
(Nishimura and Takeichi, 2008). E­cadherin, an adherens junc­
tional component, is required for proper organization of the 
circumferential actomyosin belt (Smutny et al., 2010; Yano   
et al., 2011). ZO­1 and ZO­2, tight junctional components, are 
also required (Yamazaki et al., 2008); however, the detailed 
molecular network regulating the circumferential actomyosin 
belt is not completely understood.
Our previous study demonstrated that Lulu1 and 2 (also 
known  as  Epb41l5  and  Epb41l4b/Ehm2,  respectively)  are 
potent activators of cortical myosin II contractile forces in 
epithelial cells (Nakajima and Tanoue, 2010). They commonly 
have  a  FERM  (4.1  protein,  ezrin,  radixin,  moesin)  and  a 
FERM­adjacent (FA) domain, although other portions beyond 
these domains do not resemble each other (Shimizu et al., 
2000; Lee et al., 2007; Hirano et al., 2008). From sequence 
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yosin II–driven mechanical forces control epi-
thelial cell shape and morphogenesis. In par-
ticular,  the  circumferential  actomyosin  belt, 
which is located along apical cell–cell junctions, regu-
lates  many  cellular  processes.  Despite  its  importance, 
the  molecular  mechanisms  regulating  the  belt  are  not 
fully understood. In this paper, we characterize Lulu2, 
a FERM (4.1 protein, ezrin, radixin, moesin) domain– 
containing molecule homologous to Drosophila melano-
gaster Yurt, as an important regulator. In epithelial cells, 
Lulu2  is  localized  along  apical  cell–cell  boundaries,  and 
Lulu2  depletion  by  ribonucleic  acid  interference  results 
in disorganization of the circumferential actomyosin belt.   
In  its  regulation  of  the  belt,  Lulu2  interacts  with  and   
activates p114RhoGEF, a Rho-specific guanine nucleotide 
exchanging factor (GEF), at apical cell–cell junctions. This 
interaction is negatively regulated via phosphorylation 
events in the FERM-adjacent domain of Lulu2 catalyzed 
by atypical protein kinase C. We further found that Patj, 
an apical cell polarity regulator, recruits p114RhoGEF to 
apical cell–cell boundaries via PDZ (PSD-95/Dlg/ZO-1) 
domain–mediated  interaction.  These  findings  therefore 
reveal a novel molecular system regulating the circumfer-
ential actomyosin belt in epithelial cells.
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Figure 1.  Lulu2 accumulates along apical cell–cell boundaries and regulates the circumferential actomyosin belt. (A) DLD-1 cells doubly immunostained 
for Lulu2 and ZO-1. Lulu2 accumulates along cell–cell boundaries overlapping ZO-1 (arrows). (B) Vertical images of DLD-1 cells doubly immunostained 
for Lulu2 and ZO-1. (C and D) DLD-1 cells treated with control siRNA or Lulu2 siRNA-1 were stained for F-actin, myosin IIA, diphosphorylated MRLC   247 Lulu2 regulates p114RhoGEF • Nakajima and Tanoue
a tight junctional marker (Fig. 1, A and B; and Fig. S2, A–D, 
for the specificity of the antibody). Lulu2 was also detected in 
the cytoplasm as dots (Fig. 1 A), which we did not character­
ize further in this study. In addition, as DLD­1 cells mainly 
express the short form of Lulu2 (unpublished data), it was 
used in this study.
To understand the role of Lulu2 in the epithelial cell struc­
ture, we conducted Lulu2 RNAi experiments using DLD­1 
cells (Fig. S2, C and D, RNAi). Throughout this study, we 
routinely confirmed the results of all the RNAi experiments by 
using two different siRNAs targeting each molecule, although 
we present the data of one siRNA for one molecule to avoid 
redundancy. Control RNAi cells exhibited a well­developed 
circumferential  actomyosin  belt,  indicated  by  staining  for   
F­actin and myosin IIA (Fig. 1 C). In Lulu2­depleted cells, 
in contrast, it became significantly thin with concomitant loss 
of  phosphorylated  myosin  regulatory  light  chain  (MRLC) 
from cell–cell boundaries (Fig. 1 C). These Lulu2­depleted 
cells, however, retained an apparently normal tight junction 
marked by ZO­1 staining, although cell–cell borders located 
by the staining became overly bent and less strained in Lulu2­ 
depleted cells than controls (Fig. 1, D and E). This might have 
been caused by loss of apical tension generated by the circum­
ferential actomyosin belt in Lulu2­depleted cells. In addition, 
other  tight  junctional  molecules,  including  ZO­2,  cingulin, 
Par3, and Patj, also apparently accumulated normally along 
cell–cell boundaries, further suggesting that Lulu2 might not 
regulate the localization of tight junctional molecules (Fig. 1 F  
and not depicted). In accordance with other studies that state 
the circumferential actomyosin belt regulates adherens junc­
tion (Ivanov et al., 2004, 2007; Shewan et al., 2005; Miyake 
et al., 2006; Smutny et al., 2010), in Lulu2­depleted cells,   
­catenin, a component of adherens junction, became discon­
tinuously localized at the level of zonula adherens (Fig. 1 G). 
These  results  indicate  that  Lulu2  accumulates  along  apical 
cell–cell boundaries and regulates the circumferential acto­
myosin belt (Fig. 1 H).
Lulu2 interacts with p114RhoGEF
To understand the molecular mechanism downstream of Lulu2, 
we  screened  for  interacting  molecules  by  a  GST  pull­down   
assay using a GST­fused Lulu2 FERM­FA followed by liquid   
chromatography  (LC)­mass  spectrometry  (MS)/MS  analyses 
(Fig. 2 A, FERM­FA). Adaptin , HSP70, ribosomal protein 
L4,  CWC22  splicing  factor,  heterogeneous  nuclear  ribopro­
tein U, and p114RhoGEF were identified by MS/MS (unpub­
lished data). Among them, we focused on p114RhoGEF, as it   
is  a  Rho­specific  Dbl  family  RhoGEF  (Niu  et  al.,  2003;   
Nagata and Inagaki, 2005; Tsuji et al., 2010; Terry et al., 2011),   
a good candidate molecule downstream of Lulu2. We first 
similarity, Lulus are thought to be mammalian counterparts 
of Drosophila melanogaster Yurt, which was reported to be 
a  negative  regulator  of  apical  membrane  size  in  epithelial 
cells (Hoover and Bryant, 2002; Laprise et al., 2006, 2009). 
This Yurt activity was attributed to its negative regulation of 
Crumbs, which are apical membrane regulators (Laprise et al., 
2006). Zebrafish Moe, the sole Lulu molecule in the species, 
participates in layering of the retina and inflation of the brain 
ventricles as well as restricting the photoreceptor apical do­
main (Jensen and Westerfield, 2004; Hsu et al., 2006). Moe 
also interacts with and negatively regulates Crumbs, thereby 
restricting apical membrane size in epithelial structures (Hsu 
et al., 2006). Mammalian Lulus, however, regulate myosin II 
activity rather than Crumbs activity: overexpression of Lulu1 
or  2  in  epithelial  cells  resulted  in  strong  accumulation  of   
F­actin and myosin II along apical cell–cell junctions, thereby 
inducing  apical  constriction  in  the  cells  (Nakajima  and   
Tanoue, 2010). This activity of Lulu2 is much higher than that 
of Lulu1; therefore, Lulu2 is a good candidate molecule regu­
lating the circumferential actomyosin belt. However, we did 
not explore the detailed molecular mechanisms of Lulu2 ac­
tivity in the previous study, and here, we further study Lulu2 
from cellular and molecular aspects.
We report that Lulu2 is a regulator of the circumferential 
actomyosin belt in epithelial cells. Lulu2 accumulates along 
apical cell–cell boundaries, overlapping ZO­1, and its depletion 
results  in  disorganization  of  the  circumferential  actomyosin 
belt. Lulu2 interacts with and activates the catalytic activity of 
p114RhoGEF, a Rho­specific guanine nucleotide exchanging 
factor (GEF), at apical cell–cell boundaries, thereby regulating 
the integrity of the circumferential actomyosin belt. In addition, 
Lulu2 is negatively regulated in terms of its binding ability to 
p114RhoGEF by phosphorylation in the FA domain, which is 
catalyzed  by  atypical  PKC  (aPKC).  We  further  show  that 
p114RhoGEF is recruited to apical cell–cell boundaries by Patj, 
an apicobasal cell polarity regulator. We thus propose that this 
Lulu2­p114RhoGEF system regulates the circumferential acto­
myosin belt in epithelial cells.
Results
Lulu2 accumulates along apical cell–cell 
boundaries overlapping ZO-1 and regulates 
the circumferential actomyosin belt in 
epithelial cells
We began by examining the localization of endogenous Lulu2 
in DLD­1 cells, which exhibit the characteristic morphology 
of polarized epithelial cells with a well­developed circumfer­
ential actomyosin belt (Fig. S1), and found that Lulu2 accu­
mulated along apical cell–cell boundaries, overlapping ZO­1, 
(2P-MRLC; C), or ZO-1 (D). Arrows show cell–cell boundaries. (E) Quantification of junction linearity. Junction length (blue) and the distance between ver-
tices (red) were measured in Lulu2-depleted cells or control cells. Linearity index is defined by the ratio of junction length to the distance between vertices. 
Error bars indicate SD. n = 3 independent experiments, in each of which >50 junctions were measured. **, P < 0.001 by Student’s t test. (F) DLD-1 cells 
treated with control siRNA or Lulu2 siRNA-1 were stained for Par3 or Patj. (G) DLD-1 cells treated with control siRNA or Lulu2 siRNA-1 were immunostained 
for -catenin. Arrows show zonula adherens. (bottom) Close-up views are also shown. (H) Lulu2 loss results in attenuation of the circumferential actomyosin 
belt. Bars: (A) 10 µm; (B) 2 µm; (C, D, F, and G) 20 µm.
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Figure 2.  Lulu2 interacts with p114RhoGEF. (A, top schematic) Lulu2 has a FERM and a FERM adjacent (FA) domain. Amino acid numbers of mouse 
Lulu2 are indicated. Lysates of DLD-1 cells were examined for GST pull-down assays using GST or GST-FERM-FA. Endogenous p114RhoGEF was de-
tected by immunoblotting. N, N terminus; C, C terminus. (B) Lysates of MDCK cells transfected with Flag-p114RhoGEF were examined for GST pull-down   
assays using GST, GST-FERM-FA, GST-FERM, or GST-FA (Fig. S4 B). (C) Lysates of MDCK cells cotransfected with the indicated combinations of constructs 
were immunoprecipitated (IP) with anti-Myc antibody. (top) Coprecipitated Flag-p114RhoGEF was detected by immunoblotting with anti-Flag antibody. 
Comparable amounts of Flag-p114RhoGEF were expressed (Input). (D) Lysates of DLD-1 cells were immunoprecipitated with control rabbit IgG or rabbit 
anti-Lulu2 antibody. Coprecipitated endogenous p114RhoGEF was detected by immunoblotting with anti-p114RhoGEF antibody. Characterization of the 
rabbit anti-Lulu2 antibody used is described in Fig. S2 (E and F). (E and F) DLD-1 cells doubly immunostained for Lulu2 and p114RhoGEF. Vertical images 
are shown in F. p114RhoGEF overlaps Lulu2 (arrows). (G) The in situ proximity ligation assay in DLD-1 cells. The assay was performed using goat anti-
Lulu2 and rabbit anti-p114RhoGEF antibodies (Ab). ZO-1 was also stained using mouse anti–ZO-1 antibody to identify cell–cell boundaries. The ligation 
signals (red) were detected as dots at cell–cell boundaries in the samples incubated with anti-Lulu2 and anti-p114RhoGEF antibodies but scarcely detected 
in those incubated with anti-Lulu2 antibody and control rabbit IgG or anti-p114RhoGEF antibody and control goat IgG, suggesting that Lulu2 interacts with 
p114RhoGEF at cell–cell boundaries. Cytoplasmic dots are nonspecific signals in DLD-1 cells. Quantification of numbers of ligation dots at 100 cell–cell 
boundaries is shown in the right graph. n = 3 independent experiments, in each of which 100 cell–cell boundaries were examined. Error bars indicate SD. 
**, P < 0.01 by Student’s t test. Bars: (E) 20 µm; (F) 2 µm; (G) 10 µm.249 Lulu2 regulates p114RhoGEF • Nakajima and Tanoue
specific interactions between Lulu2 and p114RhoGEF in the 
subfamily.  Supporting  this  notion,  Lulu2  scarcely  bound  to 
GEF­H1 (unpublished data).
p114RhoGEF is necessary for Lulu2 
activity in the cells and regulates the 
circumferential actomyosin belt
To examine whether p114RhoGEF was involved in myosin II 
regulation by Lulu2, we used Lulu2­expressing MDCK cells, 
which were shown in the previous study to exhibit strong myosin 
II–dependent apical constriction when mixed with nonexpressing 
parental cells (Nakajima and Tanoue, 2010). By RNAi­mediated 
p114RhoGEF depletion, apical constriction of Lulu2­expressing 
MDCK cells became impaired, indicating that p114RhoGEF is 
necessary for myosin II activation by Lulu2 (Fig. 4, A and B; and 
Fig. S3 E, RNAi). Incomplete inhibition of apical constriction 
by p114RhoGEF RNAi might be because of incomplete loss of 
p114RhoGEF in Lulu2­expressing cells by our RNAi. A trace sig­
nal of p114RhoGEF staining was still detected after RNAi treat­
ment in Lulu2­expressing cells (unpublished data).
To elucidate the role of p114RhoGEF in the organization 
of the circumferential actomyosin belt in DLD­1 cells, we ex­
amined the phenotype of p114RhoGEF­depleted DLD­1 cells 
(Fig. S3, C and D, RNAi). In p114RhoGEF­depleted DLD­1   
cells, the circumferential actomyosin belt was severely disor­
ganized because accumulation of F­actin, myosin IIA, and 
phospho­MRLC  along  apical  cell–cell  junctions  was  markedly 
reduced (Fig. 4 C). ZO­1 accumulation was not affected by 
p114RhoGEF  depletion,  although  cell–cell  borders  became 
overly bent and less strained as was the case with Lulu2­ 
depleted cells (Fig. 4, D and E). These results indicate that 
p114RhoGEF is a regulator of the circumferential actomyosin 
belt. As p114RhoGEF is a Rho­specific GEF, we postulated 
that it might be regulated by Lulu2.
Catalytic activity of p114RhoGEF  
is up-regulated by Lulu2 in vitro
The next question was therefore how Lulu2 regulates p114­
RhoGEF.  Because  Lulu2  depletion  by  RNAi  in  DLD­1   
cells  did  not  markedly  reduce  the  accumulation  of  p114­
RhoGEF at cell–cell boundaries (unpublished data), Lulu2 
might not target it there. We thus hypothesized that Lulu2 
might enhance the catalytic activity of p114RhoGEF. To test 
this idea, we measured the catalytic activity of p114RhoGEF   
in the presence or absence of Lulu2 in vitro. As both full­length 
Lulu2  and  p114RhoGEF  proteins  were  hardly  obtained  in 
bacteria,  we  prepared  full­length  proteins  from  lysates  of 
MDCK  cells  expressing  Myc­Lulu2  or  Flag­p114RhoGEF   
by  immunoprecipitation  with  antibodies  for  the  tags  fol­
lowed  by  elution  with  peptides  for  the  tags  (Fig.  4  F).   
We  first  confirmed  that  the  prepared  p114RhoGEF  has 
GEF activity toward RhoA as previously reported (Fig. 4 F;   
Nagata  and  Inagaki,  2005). When  p114RhoGEF  was  mixed 
with  Lulu2  in  the  assay,  its  GEF  activity  was  up­regulated 
(Fig.  4  F),  suggesting  that  Lulu2  activates  p114RhoGEF.   
Although further structural studies, such as determination of the 
three­dimensional structures of both molecules in a complex, 
confirmed this MS/MS result by immunoblotting using a spe­
cific antibody for p114RhoGEF (Fig. 2 A and Fig. S3, A–D, 
for the specificity of the antibody). By narrowing down the 
region of Lulu2 for binding to p114RhoGEF, we identified 
the FERM domain to be necessary and sufficient for binding   
(Fig. 2 B and Fig. S4 B). In this study, we mainly used MDCK 
cells  to  examine  interactions  of  exogenously  expressed  mol­
ecules because MDCK cells are more efficiently transfected with 
plasmids than DLD­1 cells, and MDCK cells are expected to 
have components for Lulu2 to function because Lulu2 induces 
strong apical constriction in MDCK cells (Nakajima and Tanoue, 
2010). The interaction between Myc­tagged full­length Lulu2 
and Flag­tagged full­length p114RhoGEF was also detected by   
a coexpression and coimmunoprecipitation assay (Fig. 2 C). 
Furthermore, endogenous p114RhoGEF was coimmunopre­
cipitated with endogenous Lulu2 in DLD­1 cells (Fig. 2 D and 
Fig. S2, E and F). Recently, it was reported that p114RhoGEF 
regulates RhoA activity at apical cell–cell junctions in epithelial 
cells (Terry et al., 2011). We then examined the localization of 
p114RhoGEF in DLD­1 cells and found it to be well colocalized 
with Lulu2 along apical cell–cell boundaries (Fig. 2, E and F). 
We further tested the interaction between endogenous Lulu2 and 
p114RhoGEF along cell–cell boundaries by an in situ proxim­
ity ligation assay. The ligation signals were detected at cell–cell 
boundaries overlapping ZO­1, suggesting that Lulu2 might inter­
act with p114RhoGEF there (Fig. 2 G). These results combined 
indicate  that  Lulu2  might  interact  with  p114RhoGEF  along   
apical cell–cell boundaries in epithelial cells.
Lulu2 binds to the C-terminal  
portion of p114RhoGEF, probably  
via direct interaction
We next determined the Lulu2 binding region in p114RhoGEF. 
p114RhoGEF has Dbl homology and pleckstrin homology (PH) 
domains, which are necessary for its catalytic activity, followed 
by a coiled­coil region and a potential PDZ (PSD­95/Dlg/ZO­1) 
domain–binding motif (PBM) in its C­terminal tail (Fig. 3 A).   
From sequence similarity, p114RhoGEF and three other Dbl 
RhoGEFs, p190 RhoGEF, AKAP13/Lbc, and GEF­H1, form a 
subfamily (Fig. 3 D; Schmidt and Hall, 2002; García­Mata and 
Burridge, 2007). To narrow down the region of p114RhoGEF 
interacting with Lulu2, we tested various truncated mutants of 
p114RhoGEF for binding to Lulu2 by GST pull­down assays 
using GST­FERM and identified that the region C terminal to 
the coiled­coil region without the PBM (C4PBM) was neces­
sary and sufficient for interacting with Lulu2 (Fig. 3 A). We con­
firmed this result by conducting additional pull­down assays 
using  GST­fused  truncated  mutants  of  p114RhoGEF.  Myc­
tagged full­length Lulu2 expressed in the cells was efficiently 
pulled down by GST­C2, ­C4, or ­C4PBM but not by GST, 
GST­N, or ­C1 of p114RhoGEF (Fig. 3 B and Fig. S4 B). Fur­
thermore,  p114RhoGEF  C4PBM  proteins  bound  to  Lulu2 
FERM proteins in vitro (Fig. 3 C and Fig. S4, B and C). These 
results together indicate that Lulu2 might bind to the C4PBM 
of p114RhoGEF.
Because  the  Lulu2­interacting  portion  is  poorly  con­
served among the four members (Fig. 3 D), these results suggest JCB • VOLUME 195 • NUMBER 2 • 2011   250
p114RhoGEF required for its localization at apical cell–cell 
boundaries in DLD­1 cells. The full­length and C­terminal por­
tion were recruited to apical cell–cell boundaries marked by ZO­1 
staining, whereas the N­terminal portion was not (Fig. 5). We 
thus considered that a potential PBM in its C­terminal tail might 
be responsible for its targeting and tested this possibility. It was 
found that the mutant form of p114RhoGEF that lacks the po­
tential PBM was not recruited to apical cell–cell boundaries 
(Fig. 5). Therefore, p114RhoGEF might be targeted to apical 
cell–cell boundaries via PDZ domain–mediated interaction.
are needed, we can speculate here that the binding of Lulu2 
might cause some conformational change in p114RhoGEF to 
enhance its catalytic activity.
The PBM of p114RhoGEF is required  
for targeting of p114RhoGEF to apical 
cell–cell boundaries
Because Lulu2 does not recruit p114RhoGEF to apical cell–
cell boundaries, we next investigated the targeting mechanism 
of p114RhoGEF there. We first roughly mapped the region of 
Figure 3.  Lulu2 binds to the C-terminal por-
tion  of  p114RhoGEF.  (A)  Amino  acid  num-
bers of human p114RhoGEF are indicated. 
EGFP-tagged  full-length  (FL)  or  various  trun-
cated forms of p114RhoGEF were expressed 
in  MDCK  cells  and  examined  for  binding 
to  GST  or  GST-FERM  by  GST  pull-down   
assays. C4PBM: C4 without last six amino 
acid residues. See Materials and methods for 
the  details  of  the  truncated  forms.  DH,  Dbl   
homology domain; PH, pleckstrin homology 
domain;  CC,  coiled-coil  region.  (B)  Myc-
tagged  full-length  Lulu2  was  expressed  in 
MDCK  cells  and  examined  for  binding  to 
GST-tagged truncated forms of p114RhoGEF 
by GST pull-down assays. GST fusion proteins 
used are shown in Fig. S4 B. (C) GST-fused 
C4PBM or GST was mixed and incubated 
with MBP-fused FERM or MBP in vitro and pre-
cipitated with amylose resin (MBP pull-down). 
Precipitated MBP or GST proteins (pull-down) 
were  detected  using  anti-MBP  or  -GST  anti-
bodies. Proteins used are shown in Fig. S4 B. 
See Materials and methods for details. (D) The 
Lulu2  binding  region  (red)  in  p114RhoGEF 
is  poorly  conserved  among  four  Dbl  family 
GEFs.  Numbers  indicate  similarity  between 
p114RhoGEF and the others. N, N terminus; 
C, C terminus.251 Lulu2 regulates p114RhoGEF • Nakajima and Tanoue
Figure 4.  p114RhoGEF is necessary for Lulu2 activity in the cells and is up-regulated by Lulu2 in vitro. (A and B) Mixed cell cultures of parental and 
Myc-Lulu2–expressing MDCK cells were treated with control siRNA or p114RhoGEF siRNA-1. (A) Cells were doubly immunostained for Myc and ZO-1. 
Note that Lulu2-expressing cells have higher cell heights than parental cells, resulting in the out of focus images of the parental cells. (B) Quantification of 
relative apical areas in Lulu2-expressing cells normalized by those in neighboring cells. The dotted line marks where the relative apical area is 1. n = 3 
independent experiments, in each of which >100 cells were measured. **, P < 0.01 by Student’s t test. (C and D) DLD-1 cells treated with control siRNA 
or p114RhoGEF siRNA-1 were stained for F-actin, myosin IIA, diphosphorylated MRLC (2P-MRLC; C), or ZO-1 (D). (E) Linearity index was quantified as in 
Fig. 1 E. (F) In vitro guanine nucleotide exchange reaction of p114RhoGEF toward RhoA was monitored as an increase in fluorescence, which is indica-
tive of the binding of N-methylanthraniloyl–GTP to small GTPases. p114RhoGEF possesses GEF activity toward RhoA (yellow), which is up-regulated in the 
presence of Lulu2 (blue). Three independent experiments were quantified. (left) The proteins used are detected by Western blotting (WB) with anti-Flag or 
anti-Myc antibody or stained with CBB. See Materials and methods for details. Error bars indicate SD. Bars, 20 µm.JCB • VOLUME 195 • NUMBER 2 • 2011   252
Patj recruits p114RhoGEF to apical  
cell–cell boundaries
To  identify  the  molecule  targeting  p114RhoGEF,  we  tested 
several PDZ domain–containing molecules known to be local­
ized at cell–cell boundaries for binding to p114RhoGEF by 
GST pull­down assays using the C2 fragment of p114RhoGEF. 
Among them, it was found that Patj and Par3, well­known api­
cal cell polarity regulators (Suzuki and Ohno, 2006; Goldstein 
and Macara, 2007; Assémat et al., 2008; Martin­Belmonte and 
Mostov, 2008; Pieczynski and Margolis, 2011), bound to the 
C2 fragment (Fig. S4 A). The former has 10 PDZ domains, 
and the latter has three PDZ domains. Both Myc­tagged Patj 
and Par3 expressed in the cells efficiently bound to the C2 fra­
gment  of  p114RhoGEF,  and  these  interactions  depended  on 
the putative PBM of p114RhoGEF (Fig. 6 A and Fig. S4 B).   
To know which molecule actually targets p114RhoGEF in the 
cells, we examined the relationship among p114RhoGEF, Patj, 
and Par3 in terms of their localization. As previously reported 
in other cell types (Suzuki et al., 2001; Lemmers et al., 2002; 
Shin et al., 2005; Adachi et al., 2009), in DLD­1 cells, both 
Patj and Par3 overlap ZO­1 (unpublished data). In Patj­depleted 
cells, continuous ZO­1 staining was not affected, whereas it   
became partially fragmented in Par3­depleted cells (Fig. 6 B and   
Fig. S3, F, G, I, and J, RNAi). In both Par3­ and Patj­depleted 
cells, p114RhoGEF mostly disappeared from cell–cell bound­
aries  marked  by  ZO­1  staining  (Fig.  6  B).  In  Patj­depleted 
cells, Par3 localization was not altered: Par3 still overlaps ZO­1   
(Fig. 6 C). However, in Par3­depleted cells, Patj disappeared 
from cell–cell boundaries where ZO­1 accumulated (Fig. 6 D). 
These results suggest that Par3 is upstream of Patj, and Patj is 
upstream of p114RhoGEF in terms of accumulation at cell–cell 
boundaries. In addition, the total expression level of p114RhoGEF 
protein was not affected by Patj depletion (Fig. 6 E), indicating 
that the delocalization of p114RhoGEF in Patj­depleted cells 
is not caused by down­regulation of the total protein level of 
p114RhoGEF. The interaction between GFP­tagged full­length 
p114RhoGEF and Myc­tagged full­length Patj was detected in a 
coimmunoprecipitation assay (Fig. 6 F). This interaction, as ex­
pected, required the C­terminal PBM of p114RhoGEF (Fig. 6 F).   
Furthermore,  endogenous  p114RhoGEF  was  coimmunopre­
cipitated with endogenous Patj (Fig. 6 G). In addition, cingu­
lin, which was recently reported to bind to the PH domain of 
p114RhoGEF and to be necessary for p114RhoGEF localiza­
tion along cell–cell boundaries (Terry et al., 2011), remained 
Figure 5.  The C-terminal PBM is necessary for p114RhoGEF to be localized at apical cell–cell boundaries. (top schematic) p114RhoGEF possesses a 
potential PBM (VIFF) in its C-terminal tail. DLD-1 cells transfected with EGFP-tagged full-length p114RhoGEF (FL), N-terminal portion of p114RhoGEF (N),   
C-terminal portion of p114RhoGEF (C), or p114RhoGEFPBM (FLPBM), in which its last six amino acid residues were deleted, were doubly immuno-
stained for EGFP and ZO-1. Fluorescence intensity of the EGFP or ZO-1 signal was scanned across cell–cell boundaries between control and EGFP- 
expressing cells (left and right of dotted lines, respectively). Five different cell–cell boundaries were measured (shown in different colors). (right) Vertical 
images are also shown. Although full-length and C-terminal p114RhoGEF accumulate along apical cell–cell boundaries, overlapping ZO-1, N-terminal 
p114RhoGEF, and FLPBM do not. Arrows and arrowheads show cell–cell boundaries marked by ZO-1. Bars, 10 µm.253 Lulu2 regulates p114RhoGEF • Nakajima and Tanoue
Figure 6.  Patj is necessary for p114RhoGEF to be recruited to apical cell–cell boundaries and regulates the circumferential actomyosin belt. (A) GST pull-
down was performed with GST, GST-p114RhoGEF C2, or GST-p114RhoGEF C2PBM (Fig. 3 A, C2). Myc-tagged Patj and Par3 expressed in MDCK cells 
were examined. (B) DLD-1 cells treated with control siRNA, Patj, or Par3 siRNA-1 were doubly immunostained for p114RhoGEF and ZO-1. (C) DLD-1 cells 
treated with control siRNA or Patj siRNA-1 were doubly immunostained for Par3 and ZO-1. (D) DLD-1 cells treated with control siRNA or Par3 siRNA-1 
were doubly immunostained for Patj and ZO-1. (E) DLD-1 cells treated with control siRNA or Patj siRNA-1 were analyzed by immunoblotting with anti-
p114RhoGEF antibody. (F) Lysates of MDCK cells cotransfected with the indicated combinations of constructs were immunoprecipitated (IP) with anti-Myc 
antibody. (top, GFP) Coimmunoprecipitated EGFP-p114RhoGEF was detected. Comparable amounts of EGFP-p114RhoGEF or EGFP-p114RhoGEFPBM 
were  expressed  (Input).  (G)  Lysates  of  DLD-1  cells  were  immunoprecipitated  with  anti-Patj  antibody.  Endogenous  p114RhoGEF  was  detected.   
(H and I) DLD-1 cells treated with control siRNA or Patj siRNA-1 were stained for cingulin (H), F-actin, or myosin IIA (I). (J) Mixed cell cultures of parental 
and Myc-Lulu2–expressing MDCK cells were treated with control siRNA or Patj siRNA-1. Relative apical areas in Lulu2-expressing cells normalized by those 
in neighboring cells were quantified as in Fig. 4 B. n = 3 independent experiments, in each of which >100 cells were measured. Error bars indicate SD. 
*, P < 0.05 by Student’s t test. Bars: (B, H, and I) 20 µm; (C and D) 10 µm.JCB • VOLUME 195 • NUMBER 2 • 2011   254
in which the aforementioned four aPKC phosphorylation sites 
were replaced by glutamic acids or alanines and tested them for 
the ability to induce apical constriction (Fig. 8 A). It was found 
that whereas wild­type Lulu2 and Lulu2 4A induced strong api­
cal constriction in MDCK cells, Lulu2 4E did not (Fig. 8 A), 
suggesting that the phosphorylation of these sites might nega­
tively regulate Lulu2 activity.
EGFP­tagged  wild­type  Lulu2  efficiently  accumulated 
along cell–cell boundaries marked by ZO­1 staining like en­
dogenous Lulu2 (Fig. S5). Lulu2 4A also accumulated there. 
In contrast, Lulu2 4E less efficiently accumulated there: it was 
detected diffusely in the cytoplasm (Fig. S5). Although these 
results suggest that Lulu2 localization is regulated by phosphor­
ylation, endogenous Lulu2 localization along apical cell–cell 
boundaries was not significantly changed in aPKC dominant 
negative (DN)–expressing cells (unpublished data), suggesting 
that fine, but as yet unknown, regulation might operate to regu­
late endogenous Lulu2 localization.
To examine the relationship between Lulu2 and aPKC in 
the cells, a kinase­deficient form of aPKC, which is thought to 
function as an aPKC DN (Suzuki et al., 2001), was expressed in 
the cells. aPKC DN induced apical constriction like Lulu2 in 
DLD­1 cells (Fig. 8 B). aPKC DN also induced stronger apical 
constriction in Lulu2­expressing MDCK cells than in parental 
MDCK cells (Fig. 8 C). These results suggest that aPKC might 
counteract Lulu2 activity.
In  addition,  it  was  found  that  the  phosphorylation  of 
FERM­FA by aPKC markedly reduced its ability to interact with 
p114RhoGEF (Fig. 8 D). Furthermore, aPKC­phosphorylated 
Lulu2 scarcely activated p114RhoGEF in vitro (Fig. 8 E). Lulu2 
4A bound to p114RhoGEF, whereas Lulu2 4E scarcely bound, 
further supporting the notion that phosphorylation negatively 
regulates the interaction (Fig. 8 F). Because Lulu2 normally ac­
cumulated along apical cell–cell boundaries in p114RhoGEF­
depleted DLD­1 cells (unpublished data), p114RhoGEF is not 
likely to anchor Lulu2 there. These results together suggest that 
phosphorylation of the FA domain by aPKC might negatively 
regulate Lulu2 activity on the circumferential actomyosin belt.
aPKC regulates the circumferential 
actomyosin belt as well as tight junction
We next conducted aPKC (PKC­) RNAi experiments in DLD­1   
and MDCK cells. aPKC was, as reported previously for other 
cell types, localized along apical cell–cell boundaries as well 
as at the apical membrane in both cells (unpublished data). 
By  aPKC  depletion,  both  the  circumferential  actomyosin  belt 
and tight junction marked by ZO­1 were severely disrupted in   
DLD­1 cells and MDCK cells overexpressing Myc­Lulu2 but not   
in parental MDCK cells (Fig. 8, G and H; and Fig. S3, K and L, 
RNAi). Consistent with these results, when aPKC DN­expressing   
cells formed a cell cluster, apical junctions in the cluster were 
severely disrupted in DLD­1 cells and MDCK cells expressing 
Myc­Lulu2 but not in parental MDCK cells (unpublished data). 
These results suggest that cells with high Lulu2 activity, such   
as  DLD­1  cells  and  MDCK  cells  expressing  Myc­Lulu2,   
require aPKC activity to properly maintain the apical junc­
tions and the circumferential actomyosin belt.
localized  there  in  Patj­depleted  cells  (Fig.  6  H),  suggesting 
that cingulin might not mainly serve as a targeting molecule of 
p114RhoGEF.
We next investigated the role of Patj in the organization 
of the circumferential actomyosin belt. By Patj depletion, the 
circumferential actomyosin belt was severely disrupted as with 
p114RhoGEF  depletion:  bundles  of  F­actin  and  myosin  IIA 
along the apical cell–cell boundaries were mostly lost in Patj­
depleted cells (Fig. 6 I). It was also found that Lulu2­induced 
apical  constriction  was  attenuated  in  Patj­depleted  MDCK 
cells, suggesting that Patj is required for myosin II regulation 
by Lulu2 (Fig. 6 J and Fig. S3, H and M). These results suggest 
that Patj might recruit p114RhoGEF to apical cell–cell bound­
aries and thereby regulate the integrity of the circumferential 
actomyosin belt, although we cannot exclude the possibility 
that Par3 also plays some role in targeting p114RhoGEF.
The FA domain of Lulu2 is phosphorylated 
by aPKC
Although we showed that the FERM domain of Lulu2 is suffi­
cient for interaction with p114RhoGEF, the role of the FA domain 
in the regulation of p114RhoGEF remained obscure and was   
investigated. We noticed that the FA domain of Lulu2 has sev­
eral potential PKA and PKC phosphorylation sites (Fig. 7 A) 
and hypothesized  that  Lulu2  might  be  regulated  by  phos­
phorylation of these sites. To examine whether PKA and PKC 
phosphorylate Lulu2, we performed phosphate affinity gel 
electrophoresis of GST­fused proteins subjected to in vitro   
kinase assays using the acrylamide­pendant Phos­tag ligand fol­
lowed by immunoblotting with an antibody for GST. In this way, 
we can detect a phosphorylated protein by retarding its mobility 
in electrophoresis (Kinoshita et al., 2006). Using this method, 
it was found that aPKC (PKC­), conventional PKC (PKC­), 
and PKA phosphorylate the FA domain. These kinases could 
efficiently phosphorylate the GST­fused FA domain and GST­
fused FERM­FA domain but not the GST­fused FERM domain 
in vitro (Fig. 7 B and Fig. S4, B and D–G).
As we found that aPKC and its activator Par6, both 
well­known cell polarity regulators (Suzuki and Ohno, 2006; 
Goldstein  and  Macara,  2007;  Assémat  et  al.,  2008;  Martin­ 
Belmonte and Mostov, 2008; Pieczynski and Margolis, 2011) 
bind to Myc­Lulu2 (Fig. 7 C), and aPKC can often be detected   
as a complex with its substrates, we focused on aPKC. There are 
two aPKCs, PKC­ and PKC­, which are thought to play redun­
dant roles. Using mutant forms of the FA domain, in which po­
tential PKC phosphorylation sites were replaced by alanines, it 
was found that Ser385, Ser414, Ser419, and Thr424 were phos­
phorylated by aPKC in vitro (Fig. 7 D and Fig. S4, H and I). In 
addition, the phosphorylation of Lulu2 expressed in MDCK cells, 
which mainly express PKC­ (not depicted; Suzuki et al., 2004), 
was markedly reduced by PKC­ depletion (Fig. 7 E), confirming 
an aPKC­mediated phosphorylation of Lulu2 in the cells.
aPKC negatively regulates Lulu2 activity
To examine the effect of phosphorylation on Lulu2 activity, we 
prepared a phosphorylation­mimicking (Lulu2 4E) and a phos­
phorylation­deficient  (Lulu2  4A)  form  of  full­length  Lulu2,   255 Lulu2 regulates p114RhoGEF • Nakajima and Tanoue
Figure 7.  Lulu2 is phosphorylated by aPKC. (A) Amino acid sequence of the FA domain (378–428 aa; mouse Lulu2) is shown. Potential PKA or PKC 
phosphorylation sites (NetPhosK program) are in blue or red, respectively. N, N terminus; C, C terminus. (B) GST-FERM-FA, GST-FERM domain and GST-FA 
domain were subjected to in vitro kinase assays with PKC-. Phosphorylation was detected by mobility shift patterns (bars) in Mn
2+–Phos-tag SDS-PAGE 
followed by immunoblotting with anti-GST antibody. PKC- used is shown in Fig. S4 E. See Materials and methods for details. (C, left) Lysates of MDCK 
cells expressing Myc-Lulu2 were immunoprecipitated (IP) with anti-Myc antibody. (left, top, PKC-/) Coprecipitated endogenous PKC-/ was detected. 
(right) Lysates of MDCK cells expressing Myc-Lulu2 were immunoprecipitated with rabbit control IgG or anti-Par6 antibody. (top right, Myc) Coprecipitated 
Myc-Lulu2 was detected. (D) GST-fused mutant forms of the FA domain, in which Ser385, Thr408, Ser414, Ser419, or Thr424 was replaced by alanine, 
were prepared and examined for phosphorylation by aPKC- in vitro (right, HA–PKC-), or left untreated (left, ). Phosphorylated GST-FA was detected by 
mobility shift patterns (bar) in Mn
2+–Phos-tag SDS-PAGE followed by immunoblotting with anti-GST antibody. (E) MDCK cells expressing Myc-Lulu2 were 
treated with control siRNA or PKC- siRNA-1. Phosphorylated Lulu2 was detected by mobility shift patterns (bar) in Mn
2+–Phos-tag SDS-PAGE followed by 
immunoblotting with anti-Myc antibody.JCB • VOLUME 195 • NUMBER 2 • 2011   256
Figure 8.  Lulu2 is negatively regulated by aPKC. (A) Quantification of apical areas defined by ZO-1 staining signals in EGFP-Lulu2–, EGFP-Lulu2 4A–, 
or EGFP-Lulu2 4E–expressing cells. Relative apical areas in Lulu2-expressing cells normalized by those in neighboring cells were quantified as in Fig. 4 B. 
MDCK cells were used. N, N terminus; C, C terminus. (B and C) DLD-1 cells transfected with T7-tagged wild-type aPKC- or dominant-negative aPKC (aPKC DN) 257 Lulu2 regulates p114RhoGEF • Nakajima and Tanoue
Roh et al., 2002; Hurd et al., 2003; Michel et al., 2005; Shin   
et al., 2005; Wells et al., 2006; Massey­Harroche et al., 2007; 
Sugihara­Mizuno et al., 2007; Adachi et al., 2009). We can thus 
speculate that there might exist a large molecular complex con­
taining p114RhoGEF at apical cell–cell boundaries and that 
the components of the complex might cooperatively regulate 
p114RhoGEF  depending  on  cellular  conditions.  Our  results 
here show that Lulu2 up­regulates the activity of p114RhoGEF 
by binding to it. Considering the aforementioned possible com­
plex regulation of p114RhoGEF in the cells, Lulu2, however, 
might not only activate p114RhoGEF through the simple inter­
action shown here but also cooperatively regulate it with other 
unidentified  regulators.  Therefore,  comprehensive  identifica­
tion and characterization of the possible large molecular ma­
chinery containing p114RhoGEF and Patj are needed in our future 
study to fully understand the molecular mechanisms regulating 
the circumferential actomyosin belt.
FERM domain–containing molecules are also generally 
thought to play multiple roles and have several interacting 
Discussion
We previously reported that Lulu2 overexpression in epithe­
lial cells caused strong accumulation of actomyosin bundles at 
the cell cortex and induced apical constriction (Nakajima and   
Tanoue, 2010). Here, we characterized Lulu2 as a regulator of 
the circumferential actomyosin belt in epithelial cells by study­
ing Lulu2 in more detail at the molecular level. One of the main 
findings of our present study is that Lulu2 interacts with and 
activates p114RhoGEF in its regulation of the circumferential   
actomyosin belt (Fig. 9). p114RhoGEF was recently shown to be 
an essential regulator of RhoA at apical junctions: it activates 
RhoA at apical junctions, thereby regulating the circumferential 
actomyosin belt and participating in tight junction formation in 
Ca
2+ switch experiments (Terry et al., 2011). Our results here 
also confirm the importance of p114RhoGEF in organization 
of the circumferential actomyosin belt. Its role in tight junc­
tion organization, however, might be cell­type dependent: with­
out Ca
2+ switch, p114RhoGEF depletion resulted in disruption 
of tight junctions in human corneal epithelial cells but not in 
Caco2 and DLD­1 cells (Fig. 4; Terry et al., 2011).
p114RhoGEF was reported to play multiple cellular roles 
depending on cell types and to interact with several molecules. 
p114RhoGEF participates in stress fiber formation and reactive 
oxygen species production via binding to Sept9 or the G 
subunit of heterotrimeric G proteins in fibroblasts (Niu et al., 
2003; Nagata and Inagaki, 2005) and also in neurite elonga­
tion via binding to Disheveled and Daam1in neuroblastoma   
cells (Tsuji et al., 2010). Recently, it was also reported that 
p114RhoGEF forms a complex with cingulin, myosin II, and 
Rock II and regulates RhoA activity at apical cell–cell junctions   
in epithelial cells (Terry et al., 2011). Of note, cingulin interacts 
with the PH domain of p114RhoGEF at apical cell–cell bound­
aries in epithelial cells, and its depletion resulted in delocal­
ization of p114RhoGEF from there (Terry et al., 2011). On the 
other hand, our results show that p114RhoGEF might be re­
cruited to apical cell–cell boundaries by Patj via PDZ domain–
mediated  interaction;  therefore,  Patj  and  cingulin  might 
cooperatively recruit p114RhoGEF to apical cell–cell boundar­
ies in an as yet unknown fashion. Other known p114RhoGEF­
interacting  molecules  also  could  interact  with  and  regulate 
p114RhoGEF at apical cell–cell boundaries in epithelial cells, 
although these possibilities have not been tested yet. Furthermore, 
Patj, which has 10 PDZ domains, also has several interacting 
molecules, including Pals1, angiomotin, JAM1, ZO­3, nectins, 
and Par6, at apical cell–cell boundaries (Lemmers et al., 2002; 
were stained for T7 and ZO-1 (B). Parental or Lulu2-expressing MDCK cells were transfected with T7–aPKC DN and stained for T7 and ZO-1 (C). Relative 
apical areas in aPKC-expressing cells normalized by those in neighboring cells were quantified as in Fig. 4 B. Singly locating aPKC-expressing cells sur-
rounded by nonexpressing cells were measured. Arrows show T7-aPKC–expressing cells. (D) GST-FERM-FA phosphorylated by aPKC- was examined for 
binding to p114RhoGEF by GST pull-down assays. Phosphorylated (ATP+) or unphosphorylated (ATP) GST-FERM-FA was incubated with lysates of MDCK 
cells expressing Flag-p114RhoGEF (Lysate) or with eluted Flag-p114RhoGEF (Eluted). Coprecipitated Flag-p114RhoGEF was detected by anti-Flag anti-
body. See Materials and methods for details. (E) In vitro guanine nucleotide exchange reaction of p114RhoGEF toward RhoA. aPKC-phosphorylated Lulu2 
was incubated with p114RhoGEF (red). See Materials and methods for details. (F) Flag-tagged wild-type Lulu2, Lulu2 4A, and Lulu2 4E were examined for 
binding to HA-tagged p114RhoGEF in coimmunoprecipitation (IP) assays. Coprecipitated HA-p114RhoGEF was detected (HA). (G) DLD-1 cells treated with 
control siRNA or PKC- siRNA-1 were stained for ZO-1, F-actin, or myosin IIA. (H) Parental MDCK cells or MDCK cells overexpressing Myc-Lulu2 treated 
with control siRNA or PKC- siRNA-1 were stained for ZO-1. n = 3 independent experiments, in each of which >50 cells were measured. Error bars indicate 
SD. *, P < 0.05 by Student’s t test. Bars, 20 µm.
 
Figure 9.  Schematic representation of Lulu2 involvement in regulation of 
the circumferential actomyosin belt. Lulu2 activates p114RhoGEF, thereby 
regulating  the  circumferential  actomyosin  belt.  Lulu2  is  phosphorylated 
in the FA domain and negatively regulated by aPKC. p114RhoGEF is   
recruited to apical cell–cell boundaries by Patj via PDZ domain–mediated 
interaction. Par3 regulates Patj accumulation at apical cell–cell bounda-
ries. P, phosphorylation; DH, Dbl homology domain; PH, pleckstrin homol-
ogy domain; CC, coiled-coil region.JCB • VOLUME 195 • NUMBER 2 • 2011   258
findings  concerning  phosphorylation­mediated  Lulu2  regula­
tion might be of importance. We found that aPKC, an apico­
basal  cell  polarity  regulator,  phosphorylates  and  negatively 
regulates Lulu2. In accordance with our results, it was also re­
ported that aPKC antagonizes myosin II activity of the circum­
ferential actomyosin belt (Kishikawa et al., 2008; Mashukova   
et al., 2011). To establish the epithelial cell structure, regulation 
of  the  circumferential  actomyosin  belt  and  apicobasal  cell   
polarity might not be independent but interdependent events. 
The aPKC–Lulu2 pathway might thus be one of the connec­
tions between these two cellular processes. In the regulation of 
myosin II activity of the belt, Lulu2 is obviously not a sole tar­
get of aPKC. It was recently reported that aPKC phosphorylates 
and inhibits Rock1 from accumulating to the apical junctions, 
thereby  negatively  regulating  myosin  II  activity  of  the  belt 
(Ishiuchi and Takeichi, 2011). How these two systems, aPKC–
Lulu2­p114RhoGEF  and  aPKC­Rock1,  are  spatiotemporally 
regulated might be an interesting future problem to be addressed. 
In addition, we found that conventional PKC and PKA also 
phosphorylate the FA domain of Lulu2, although we did not   
explore the functional relevance of these phosphorylations in 
this study. Because both kinases are downstream of several   
extracellular stimuli, it would be important to identify the 
stimuli that lead to the phosphorylation of Lulu2 by these   
kinases in future studies.
In  summary,  we  demonstrated  here  that  the  Lulu2­
p114RhoGEF system is a regulator of the circumferential 
actomyosin belt. We further showed that aPKC and Patj, apical 
cell polarity regulators, regulate the circumferential actomyo­
sin belt through the Lulu2­p114RhoGEF system, at least in 
part. Elucidating the more detailed mechanisms regulating the 
Lulu2­p114RhoGEF system is a future important challenge to 
understand epithelial cell shape regulation.
Materials and methods
Cell culture and immunostaining
MDCK cells (Tet-Off; Takara Bio Inc.) and DLD-1 cells, human colon epi-
thelial cells, were cultured in a 1:1 mixture of DME and Ham’s F12 me-
dium (Wako Chemicals USA) supplemented with 10% fetal calf serum. 
These cells were maintained in 5% CO2 at 37°C. The stable MDCK Tet-
Off Lulu2 transfectants were cultured in the presence of 1 µg/ml doxycy-
cline (Takara Bio Inc.). To induce the expression of Lulu2, the cells were 
washed twice at 12-h intervals and cultured in doxycycline-free medium 
for 2–3 d. Cells were transfected using a reagent (Lipofectamine LTX;   
Invitrogen) according to the manufacturer’s protocol. Immunostaining was 
performed as follows: in brief, cells were fixed with 1 or 3.7% formalde-
hyde in PBS for 10 min at RT. The fixed cells were then permeabilized 
with 0.2% Triton X-100 in PBS for 10 min and blocked with 3% BSA in 
PBS for 30 min at 37°C. Thereafter, the cells were incubated with the 
appropriate antibodies in 3% BSA in PBS for 1.5 h at 37°C. Next, the 
cells were washed five times with PBS and incubated with fluorochrome- 
conjugated secondary antibodies (1:400, Alexa Fluor secondary anti-
bodies; Invitrogen or Jackson ImmunoResearch Laboratories, Inc.) in 3% 
BSA in PBS for 1 h at 37°C. After five washes with PBS and then rinsing in 
water (Milli-Q; Millipore), coverslips were mounted with Mowiol (EMD). 
Alexa Fluor 488 phalloidin (1:200; Invitrogen) was used to visualize   
F-actin. Images were taken with a microscope (BX51; Olympus) equipped 
with a charge-coupled device camera system (DP71; Olympus) at RT.   
A UPlanSApo 20×/0.75 NA lens and a UPlanSApo 40×/0.95 NA lens 
(Olympus) were used. Images were analyzed with DP Manager software 
(Olympus) and Photoshop (Adobe). Confocal images were taken with a 
laser-scanning confocal microscope (LSM510; Carl Zeiss) mounted on an 
inverted microscope (Axiovert 200M; Carl Zeiss) using a Plan Apochromat 
molecules according to the cellular processes in which they   
participate (Tepass, 2009; Fehon et al., 2010). Lulu2 might also 
participate in other cellular processes besides the regulation of 
the  circumferential  actomyosin  belt.  Supporting  this  notion, 
Lulu2 is detected not only along apical cell–cell boundaries 
but also in the cytoplasm as dots, and our screening for inter­
acting  molecules  of  Lulu2  also  identified  several  molecules   
besides p114RhoGEF, although we did not confirm these inter­
actions in this study. Lulu2 could regulate or be regulated 
by these molecules in as yet unidentified cellular processes. 
Although we cannot therefore exclude from our results the pos­
sibility that other unidentified binding partners of Lulu2 in ad­
dition to p114RhoGEF could also participate in the regulation 
of the circumferential actomyosin belt, we can conclude that 
p114RhoGEF is the major downstream target of Lulu2 in the 
regulation of the circumferential actomyosin belt.
At  apical  cell–cell  boundaries,  Lulu2  interacts  with 
p114RhoGEF and p114RhoGEF interacts with Patj. However, 
Lulu2 is not likely to form such a tight molecular complex 
with  p114RhoGEF  that  regulates  the  localization  of  Lulu2: 
p114RhoGEF  depletion  did  not  alter  Lulu2  localization  and 
vice versa. Lulu2 therefore might be recruited to apical cell–cell 
boundaries by an as yet unidentified molecule/mechanism and 
associate with, but not be anchored by, p114RhoGEF at apical 
cell–cell boundaries.
The circumferential actomyosin belt is positioned along 
the apical cell–cell boundaries, close to both the zonula adher­
ens and tight junction, although the majority of the actomyosin 
fibers are localized near the zonula adherens (Ivanov et al., 
2007; Yamazaki et al., 2008; Smutny et al., 2010; Yonemura   
et al., 2010). Our results show that Patj and aPKC, both known 
to accumulate at the level of the tight junction, not the zonula 
adherens, regulate the circumferential actomyosin belt. It was 
also reported that ZO­1 and ZO­2, scaffolding molecules at the 
tight junction, are required for proper organization of the cir­
cumferential actomyosin belt and the zonula adherens as well   
as the tight junction itself (Yamazaki et al., 2008). It could thus   
be speculated that molecules associated with the tight junc­
tion might regulate the proper organization of the circumferen­
tial actomyosin belt. On the other hand, E­cadherin, the main 
component of the zonula adherens, also regulates the circumfer­
ential actomyosin belt (Shewan et al., 2005; Smutny et al., 2010). 
Conversely, the circumferential actomyosin belt also regulates 
proper  organization  of  the  zonula  adherens  (Shewan  et  al., 
2005; Ivanov et al., 2007; Smutny et al., 2010). Therefore, the 
formation and maintenance of these three structures, the tight 
junction, zonula adherens, and the circumferential actomyosin 
belt, are obviously mutually dependent. Temporal and spatial 
fine regulations thus should exist to properly regulate their or­
ganization. Studying the Lulu2­p114RhoGEF system in more 
detail might contribute to understanding the regulation of these 
pivotal architectures in polarized epithelial cells.
The circumferential actomyosin belt serves as a major 
generator of mechanical force during animal morphogenesis. 
Accordingly, it should not be a static structure but rather dy­
namic and flexible. Several signaling pathways might regulate 
it at an appropriate time and place. From this viewpoint, our 259 Lulu2 regulates p114RhoGEF • Nakajima and Tanoue
(human), 5-UGGCCACAAUGAAGCUGUUAGUCAU-3; p114RhoGEF 
siRNAi-2 (human), 5-GAUGGACCUGAAGUCUUCCAGCAAA-3; Par3 
siRNAi-1 (human), 5-CAAGCCAUGCGUACACCCAUCAUUU-3; Par3 
siRNAi-2 (human), 5-CCUGAGCAGAUAGACUCUCACUCAA-3; Patj   
siRNAi-1 (human), 5-GCAGAUGAUGCUGAGUUACAGAAAU-3; Patj   
siRNAi-2 (human), 5-GCAUGAAUUUCUGACUCCUAGAUUG-3; Patj   
siRNAi-1  (canine),  5-UGGAGCAGUGGAAACGGAAACUAAU-3;  Patj   
siRNAi-2  (canine),  5-GCAGAUGAUGCUGAGUUACAGAAAU-3;   
p114RhoGEF siRNAi-1 (canine), 5-UGGCCACAAUGAGGCGGUCAAUC-
  AU-3; p114RhoGEF siRNAi-2 (canine), 5-GGCCAACGAGGAGAAAGCCAUGU
UU-3; PKC- siRNAi-1 (canine and human), 5-CAGAGGAUUAUCUCU-
UCCAAGUUAU-3;  and  PKC-  siRNAi-2  (canine  and  human), 
5-AGGAGAAGAUUAUGGUUUCAGUGUU-3.
Western blotting
Cells were homogenized or lysed in 20 mM Tris-HCl, pH 7.4, containing 
1.5 mM MgCl2, 1.5 mM EGTA, 150 mM NaCl, 0.5% NP-40, 10% 
glycerol, 1 mM phenylmethylsulfonyl fluoride, and 20 µg/ml aprotinin. For   
Mn
2+–Phos-tag SDS-PAGE, EGTA was not included. Proteins were fraction-
ated by SDS-PAGE using a 7, 10, or 15% gel. Prestained molecular markers 
(Nacalai or New England Biolabs, Inc.) were used. The fractionated pro-
teins were electroblotted onto polyvinyldifluoride membranes (Immobilon-P;   
Millipore)  using  a  semidry  transfer  apparatus  (Bio-Rad  Laboratories). 
The membrane was blocked with 2% blocking agent (ECL Advance; GE 
Healthcare) for 30 min at RT. Proteins were then probed for 16 h at 4°C 
with  an  appropriate  antibody  in  20  mM  Tris-HCl,  pH  7.4,  containing   
150 mM NaCl and 3% BSA or in 20 mM Tris-HCl, pH 7.4, containing   
150 mM NaCl, 0.05% Tween 20, and 0.2% ECL Advance blocking agent. 
The membrane was then washed three times at room temperature (15 min 
each time) in 20 mM Tris-HCl, pH 7.4, containing 150 mM NaCl and 
0.05% Tween 20 (TBS-Tween) and was subsequently incubated for 2 h at 
RT with a secondary antibody in TBS-Tween containing 3% BSA or 2% ECL 
Advance blocking agent. After three washes with TBS-Tween, the proteins 
were detected using ECL Advance reagent according to the manufacturer’s 
protocol. Chemiluminescence was detected using an imager (ImageQuant 
400; GE Healthcare).
Immunoprecipitation and GST pull-down assay
For immunoprecipitation, the cells were lysed in lysis buffer (20 mM Tris-
HCl, pH 7.4, containing 150 mM NaCl, 0.5% NP-40, 1.5 mM MgCl2, 
1.5 mM EGTA, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, and 
20 µg/ml aprotinin). Lysates were incubated with an appropriate anti-
body and protein A–Sepharose (GE Healthcare) or anti-Flag M2 affinity 
gel (Sigma-Aldrich) for 2 h at 4°C. The beads were subsequently washed 
three times in lysis buffer.
For GST pull-down assays, cells were lysed in lysis buffer (20 mM 
Tris-HCl, pH 7.4, containing 150 mM NaCl, 0.5% NP-40, 1.5 mM MgCl2, 
1.5  mM  EGTA,  10%  glycerol,1  mM  phenylmethylsulfonyl  fluoride  and   
20 µg/ml aprotinin). GST fusion proteins and glutathione–Sepharose 4B 
beads (GE Healthcare) were added to the lysate. After a 4-h incubation at 
4°C, the beads were washed four times in lysis buffer. The obtained sam-
ples were analyzed by Western blotting or LC-MS/MS. For LC-MS/MS, 
bands identified by staining using an MS-grade silver staining kit (Wako 
Chemicals USA) or fluorescent gel stain (Oriole; Bio-Rad Laboratories) after 
SDS-PAGE were analyzed in the Center for Mass Spectrometry at Kobe 
University Graduate School of Medicine.
Proximity ligation assay
The proximity ligation assay was performed using an in situ proximity liga-
tion assay kit (Duolink II; Olink Bioscience) according to the manufacturer’s 
instructions. The ligation signals indicate the proximity (<40 nm) of second-
ary antibodies detecting anti-Lulu2 antibodies bound to Lulu2 to those de-
tecting anti-p114RhoGEF antibodies bound to p114RhoGEF.
In vitro binding assay
In Fig. 3 C, GST-tagged C4PBM, GST, MBP-tagged FERM-FA, and MBP 
were prepared in bacteria. GST-tagged C4PBM or GST (0.2 µg each) 
was mixed and incubated for 2 h at RT with MBP-tagged FERM or MBP   
(1 µg each) and then precipitated with amylase/agarose beads (New Eng-
land Biolabs, Inc.). The beads were subsequently washed three times in 
TBS (20 mM Tris-HCl, pH 7.4, and 150 mM NaCl). Coprecipitated GST-
C4PBM was detected by Western blotting using the anti-GST antibody.
In  Fig.  8  D,  Flag-p114RhoGEF  was  immunoprecipitated  from   
lysates of MDCK cells expressing Flag-p114RhoGEF and then eluted with   
0.1 mg/ml Flag peptides (Sigma-Aldrich). The eluted Flag-p114RhoGEF pro-
tein was incubated with phosphorylated or unphosphorylated GST-FERM-FA 
63×/1.40 NA objective and LSM510 software (Carl Zeiss) at RT. Images 
were analyzed with the same software and with Photoshop software or 
ImageJ (National Institutes of Health). The apical area of MDCK cells was 
measured using ImageJ software. Fluorescent intensities were measured 
by counting gradient values using ImageJ software.
Antibodies
The  following  antibodies  were  used:  mouse  monoclonal  antibodies 
against -catenin (BD), ZO-1 (Invitrogen), CASK (Millipore), Dlg1 (Santa 
Cruz  Biotechnology,  Inc.),  Flag  (M2;  Sigma-Aldrich),  GST  (Nacalai), 
PKC- (BD), Scribble (Santa Cruz Biotechnology, Inc.), -tubulin (Sigma- 
Aldrich), maltose-binding protein (MBP; New England Biolabs, Inc.), Myc 
(9E10; Santa Cruz Biotechnology, Inc.), and MUPP1 (BD); rat monoclonal 
antibody against GFP (Nacalai); rabbit polyclonal antibodies against 
Afadin (Sigma-Aldrich), -catenin (Sigma-Aldrich), cingulin (Invitrogen), 
p114RhoGEF  (Gentex),  ZO-1  (Invitrogen),  ZO-2  (Invitrogen),  MAGI-1 
(Sigma-Aldrich), myosin IIA (Sigma-Aldrich), diphosphorylated MRLC (Cell 
Signaling Technology), Flag (Sigma-Aldrich), HA (MBL International), Myc 
(Santa Cruz Biotechnology, Inc.), Par3 (Millipore), Pals1 (Millipore), GST 
(MBL International), Par6 (Sigma-Aldrich), aPKC-/ (Santa Cruz Biotech-
nology, Inc.), Patj (Abcam), T7 (MBL International), and GFP (MBL Inter-
national); goat polyclonal antibody against Lulu2/Ehm2 (Abcam); control 
goat IgG (Santa Cruz Biotechnology, Inc.); and control rabbit IgG (Santa   
Cruz Biotechnology, Inc.). Rabbit anti-Patj antibody used for immunostaining 
was a gift from A. Le Bivic (Centre National de la Recherche Scientifique, 
Marseille, France). Rabbit anti-Lulu2 antibody used in the immunoprecipi-
tation assay in Fig. 2 D was raised against mouse Lulu2/Ehm2 peptide 
(451–466 aa). Primary antibodies were visualized with goat or chicken 
fluorochrome-conjugated secondary antibodies. The fluorochromes used 
were Alexa Fluor 488, 549, 555, and 568 (Invitrogen or Jackson Immuno-
Research Laboratories, Inc.).
Plasmid construction and protein expression
Mouse cDNA of Lulu2-S, the short form of Lulu2 (Nakajima and Tanoue, 
2010), was provided by J. Yokota (National Cancer Center Research Insti-
tute, Tokyo, Japan). Lulu2 has two alternatively spliced transcripts that share 
FERM and FA domains in their N-terminal portions (Nakajima and Tanoue, 
2010). The full-length form of Lulu2-S was cloned into pEGFP-C1 (Takara 
Bio Inc.), pFlag-cytomegalovirus (CMV)-6C (Sigma-Aldrich), pCMV-3Tag-2 
(Agilent Technologies), or pTRE2hyg (Takara Bio Inc.), in which three Myc 
tags were attached to the N terminus. The FERM (85–367 aa), FERM-FA 
(85–428 aa), and FA (378–428 aa) domains of Lulu2 were obtained by 
PCR and cloned into pEGFP-C1. Full-length human cDNA of p114RhoGEF 
was obtained by PCR from a cDNA template (KIAA0521; Kazusa DNA 
Research Institute) and then cloned into pEGFP-C2 (Takara Bio Inc.), pFlag-
CMV-6C, or pTRE2hyg, in which a Flag tag was attached to the N terminus. 
Truncated mutant forms of p114RhoGEF (N-terminal domain: 1–441 aa; 
C-terminal domain: 452–1,015 aa; C1: 452–643 aa; C2: 644–1,015 
aa; C2PBM: 644–1,009 aa; C3: 633–800 aa; C4: 799–1,015 aa; 
C4PBM: 799–1,009 aa; and FLPBM: 1–1,009) were cloned into pEGFP-
C2  or  pGEX-4T-1  (GE  Healthcare).  pTB701-HA–PKC-  was  a  gift  from   
N. Saito (Kobe University, Kobe, Japan). pGEX-2T-RhoA was a gift from 
K. Kaibuchi (Nagoya University, Chikusa-ku, Nagoya, Japan). pCAGGS-
Myc-Par3, pCAGGS-HA–aPKC- and pCAGGS-Patj-Myc were gifts from M. 
Adachi (Kyoto University, Kyoto, Japan). SRHisB-T7–aPKC- and SRHisB-
T7–aPKC- K273E (aPKC DN) were gifts from S. Ohno (Yokohama City 
University, Hodogaya-ku, Yokohama, Japan). pGEX-4T1 or pGEX-4T3 vec-
tor (GE Healthcare) was used to produce GST-fused various mutant of Lulu2 
and p114RhoGEF in Escherichia coli. For MBP-fused protein production in 
E. coli, pMAL-c2 vector (New England Biolabs, Inc.) was used.
Mutagenesis
The mutants used were constructed by PCR-based mutagenesis. PCR was 
performed  using  DNA  polymerase  (PfuTurbo;  Agilent  Technologies).   
A  DpnI  restriction  enzyme  (Agilent  Technologies)–treated  PCR  product   
was transformed into E. coli. Positive clones were selected, and mutagen-
esis was verified by sequencing.
RNAi
Stealth  RNAi  negative  control  (Invitrogen)  was  used  for  control  RNAi. 
Transfection of Stealth siRNA was performed using a reagent (RNAiMAX; 
Invitrogen). In each RNAi experiment, essentially the same results were 
obtained using two independent RNAi sequences. The following Stealth 
siRNA  were  used  for  RNAi  experiments:  Lulu2  siRNAi-1  (human),   
5-CACCUUUGAGAGGAAGCCUAGUAAA-3;  Lulu2  siRNAi-2  (human), 
5-CGGAGACAUUCAACGUUCAAAGCAA-3; p114RhoGEF siRNAi-1 JCB • VOLUME 195 • NUMBER 2 • 2011   260
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and then precipitated with glutathione-SH beads (GE Healthcare). The 
beads were subsequently washed three times in the lysis buffer. Copre-
cipitated Flag-p114RhoGEF was detected by Western blotting using the 
anti-Flag antibody.
In vitro kinase assay
MDCK cells transfected with pSR--HA–PKC- or pTB701-HA–PKC- were 
lysed in lysis buffer (20 mM Tris-HCl, pH 7.4, containing 150 mM NaCl, 
0.5% NP-40, 1.5 mM MgCl2, 1.5 mM EGTA, 10% glycerol, 1 mM sodium 
vanadate, 1 mM phenylmethylsulfonyl fluoride, and 20 µg/ml aprotinin). 
HA-PKC protein was immunoprecipitated from cell lysates (10
6 cells in 
each sample) by incubation with 2 µg HA antibody (MBL International) 
and 15 µl protein A–Sepharose beads for 2 h at 4°C. The precipitate was 
washed three times with the lysis buffer and then washed with Tris buffer 
(20 mM Tris-HCl, pH 7.4). The HA-tagged kinases were then eluted with 
1 mg/ml HA peptides (Roche). The eluted kinase was mixed with 0.4 µg   
GST-fused Lulu2 proteins in a kinase reaction buffer (20 mM Tris-HCl,   
pH 7.5, 12.5 mM MgCl2, 1 mM DTT, 2 mM 2-glycerophosphate, 2 mM   
sodium vanadate, 10 mM NaF, and 100 µM ATP (Sigma-Aldrich); 10× PKC 
Lipid Activator (Millipore) and 2 mM CaCl2 were also included for conven-
tional PKC-) and incubated for 1 h at 30°C for PKC- or 16 h at 30°C for 
PKC-. Phosphorylation was detected by Western blotting using the Phos-
tag system (Wako Chemicals USA), a detection system of phosphorylated 
proteins using the dinuclear manganese complex of acrylamide-pendant 
Phos-tag as a phosphate-binding tag. Phos-tag was used at 25 µM. In   
Fig. 8 D, 1.5 µg GST-FERM-FA with glutathione-SH beads was incubated 
with HA–PKC- in the presence (Fig. 8 D, ATP+) or absence (Fig. 8 D, ATP) 
of ATP in the kinase reaction buffer and used for the binding assays.
In vitro GEF assay
Flag-tagged  p114RhoGEF  and  Myc-tagged  Lulu2  were  immunoprecipi-
tated from MDCK cells expressing each protein using anti-Flag M2 affinity 
gel or Myc (9E10; Santa Cruz Biotechnology, Inc.) antibody. After three 
washes with lysis buffer, the proteins were eluted with Flag or Myc pep-
tides (Sigma-Aldrich). Amounts of the obtained proteins were routinely de-
termined by Coomassie brilliant blue (CBB) or Oriole staining using BSA as 
a standard after SDS-PAGE. The obtained proteins were then used for the 
GEF assay. In Fig. 8 E, immunoprecipitated Myc-tagged Lulu2 with protein 
A–Sepharose beads was incubated with eluted HA–PKC- in the presence 
of ATP in the kinase reaction buffer for 3 h at 30°C. After washing three 
times with TBS, Myc-tagged Lulu2 was eluted with Myc peptides and then 
used for the GEF assay.
Initially, 2 µM GST-RhoA-GDP was added to the GEF assay buffer   
(20 mM Tris-HCl, pH 7.5, containing 50 mM NaCl, 10 mM MgCl2,   
1 mM DTT, 50 µg/ml BSA, 10% glycerol, and 400 nM N-methylanth-
raniloyl–GTP [Invitrogen]) and equilibrated for 5 min at 25°C. The reaction 
was initiated by the addition of 0.1 µM p114RhoGEF in the presence or 
absence of 0.1 µM Lulu2, and fluorescence was monitored at 25°C   
using a spectrofluorometer (ex = 360 nm; em = 440 nm; slits = 3/10 nm;   
FP-6500; JASCO). The guanine nucleotide exchange reaction was moni-
tored as an increase in fluorescence, which is indicative of the binding of 
N-methylanthraniloyl–GTP to GST-RhoA.
Statistical analysis
P-values were calculated by Student’s t test using Excel (Microsoft).
Online supplemental material
Fig. S1 shows that DLD-1 cells exhibit the characteristic morphology of 
polarized epithelial cells with a well-developed circumferential actomyo-
sin belt. Fig. S2 shows the characterization of the anti-Lulu2 antibodies 
and the efficiency of Lulu2 RNAi. Fig. S3 shows the characterization of 
the anti-p114RhoGEF antibody and the efficiencies of the p114RhoGEF, 
Patj, Par3, and aPKC RNAi. Fig. S4 shows the CBB images of the bacteri-
ally expressed proteins and that Patj and Par3 bound to the C2 region 
among several PDZ molecules, p114RhoGEF C4PBM bound to Lulu2 
FERM in vitro, and PKA and PKC-, but not CKI-, also phosphorylated 
Lulu2.  Fig.  S5  shows  that  exogenously  expressed  wild-type  Lulu2  and 
Lulu2 4A accumulated along apical cell–cell boundaries, whereas Lulu2 
4E did not. Online supplemental material is available at http://www.jcb 
.org/cgi/content/full/jcb.201104118/DC1.
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